Marigold (Tagetes erecta L.) has long been used as a medicinal herb for a number of therapeutic activities. In the present study, the cytotoxicities of ethanol and ethyl acetate extracts of marigold flowers and their inhibitory effects on elastase and tyrosinase enzymes were investigated. An MTT assay was performed to measure the cytotoxicity of these two extracts on the H460 lung cancer and the Caco‑2 colon cancer cell lines. An elastase assay kit, based on the digestion of a non‑fluorescent elastin substrate to highly fluorescent fragments by elastase, was used for the elastase inhibition assay. Tyrosinase inhibition activity was investigated using the dopachrome method with L-3,4-dihydroxyphenylalanine (L‑DOPA) as a substrate. The data obtained in this study demonstrated that the extracts were nontoxic to H460 and Caco‑2 cell lines. The elastase inhibition activities of ethanol (250 µg/ml) and ethyl acetate (125 µg/ml) extracts were found to be significantly higher than that of the negative control. The tyrosinase inhibition activities of ethanol and ethyl acetate extracts, in terms of the mean inhibition concentration (IC50), were 1,078 and 1,467 µg/ml, respectively. To the best of our knowledge, the present study has demonstrated for the first time that marigold flower extracts possess tyrosinase inhibition activity. The activities of ethanol and ethyl acetate extracts of marigold flowers were investigated in vitro and indicated that these extracts possess useful properties that may be of interest for cosmetic development.
Andrographolide is a labdane diterpenoid herb, which is isolated from the leaves of Andrographis paniculata, and widely used for its potential medical properties. However, there are no reports on the effects of andrographolide on the human suprapatellar fat pad of osteoarthritis patients. In the present study, our goal was to evaluate the innovative effects of andrographolide on viability and Tri-lineage differentiation of human mesenchymal stem cells from suprapatellar fat pad tissues. The results revealed that andrographolide had no cytotoxic effects when the concentration was less than 12.5 µM. Interestingly, andrographolide had significantly enhanced, dose dependent, osteogenesis and chondrogenesis as evidenced by a significantly intensified stain for Alizarin Red S, Toluidine Blue and Alcian Blue. Moreover, andrographolide can upregulate the expression of genes related to osteogenic and chondrogenic differentiation, including Runx2, OPN, Sox9, and Aggrecan in mesenchymal stem cells from human suprapatellar fat pad tissues. In contrast, andrographolide suppressed adipogenic differentiation as evidenced by significantly diminished Oil Red O staining and expression levels for adipogenic-specific genes for PPAR-γ2 and LPL. These findings confirm that andrographolide can specifically enhance osteogenesis and chondrogenesis of mesenchymal stem cells from human suprapatellar fat pad tissues. It has potential as a therapeutic agent derived from natural sources for regenerative medicine.
In situ calcium pectinate-coated pellets were proposed by applying an alternate coating method to drug-layered pellets to achieve colon-specific drug delivery. Solution layering of metroprolol tartrate, a water-soluble model drug, on inert core pellets was achieved using a centrifugal granulator followed by successive alternate coating with pectin and calcium chloride layers using a fluidized bed bottom spray coater. The effect of the coating sequence on the drug release was studied in phosphate buffer pH 7.4 and 6.0. These test conditions were used to mimic the physiological environments in the distal small intestine and proximal colon, respectively. The results showed that the in situ calcium pectinate layer was successfully generated from the alternate coating of pectin and calcium layers after hydration to form gelation, which was able to control the drug release. The coating sequence played an important role in the drug release. The outermost pectin layer tended to retard the drug release whilst the outermost calcium layer accelerated the release regardless of the number of coating layers. These findings indicate that the release behavior followed the Higuchi model, with the drug release from the coated pellets described by a diffusion control mechanism. It is concluded that the success of the in situ calcium pectinate-coated pellets in controlling the drug release is due to the coating of the outermost layer with pectin and the maintenance of the optimum ratio of calcium to pectin upon hydration.
20 January 2011 in Drug Development and Industrial Pharmacy
The aims of this study were to prepare and evaluate chitosan-polyacrylic acid complex (CS-PAA) as polymeric osmogents for swellable micro/nanoporous osmotic pump propranolol tablets. The complexes were characterized and evaluated for their swelling characteristics. The selected complexes were incorporated into the core propranolol tablets as polymeric osmogents. The core tablets were formulated, compressed as monolithic and two-layered tablets, and finally coated with cellulose acetate containing PEG 400 and PVP K30 as plasticizers and pore formers, respectively. As a final point, the drug release was determined. A direct correlation was found between the CS content in the complex and the maximum swelling force and swelling ratio of the complex mixture. In vitro drug release revealed that the percent drug release increased with the amount of osmogent in the two-layered tablets. Drug release could be prolonged up to 12h and conformed to the USP 31 criteria. In contrast, percent release decreased with the increasing amount of complexes in monolithic tablets. It was postulated that two opposing mechanisms were involved. Following water uptake, the complexes of polymers swelled and pushed the drug out of the tablets, and the drug bound to the polymer network and remained in the tablets. The results indicated that the complex of CS-PAA at optimal proportion and amount was a promising polymeric osmogent for a zero-order controlled release from two-layered swellable micro/nanoporous osmotic pump tablets.